Our early-phase formulation development services help to resolve drug delivery challenges encountered at both preclinical and clinical development stages of small molecules and peptides. We offer specific solutions to your preformulation and formulation needs through customized development strategies and designs.
Our expert team of scientists have successfully delivered projects in wide range of areas like incomplete dissolution, low solubility, low oral bioavailability and targeted drug delivery through in-depth molecular characterization, various solubilization and enabling technologies.
Many hits and lead NCEs get shelved from pharmacological and toxicity screening despite high potency because of poor bioavailability or suboptimal formulation. As a leading CDMO company, we have more than a decade of experience in helping our clients overcome these challenges by enabling preclinical and GLP toxicology studies.
Our preclinical formulation development approach considers but is not limited to
Our formulation team has the expertise in troubleshooting complex problems by banking various oral bioavailability enhancement strategies to accelerate your drug discovery program to the next phase.
Formulation development strategies are:
Our data-driven approach enables our partners to advance candidates and select the most optimal formulation for a specific drug development phase.
Services from early formulation to clinical manufacturing
Experience with advanced formulation technologies
Integration with biology services for in vitro and in vivo studies
APRIL 24, 2023
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...Read More
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....Read More
Our manufacturing services cater to both GMP and non-GMP manufacturing for pre-clinical development as well as GMP operation to support clinical or commercial needs for any recombinant proteins expressed in suspension mammalian culture or E. coli. ...Read More
Background: Develop oral liquid dosage form of an IND candidate (small molecule) suitable for chronic toxicology studies in dogs. Must meet required systemic exposure and shall be dose proportional. Developed vehicle or used excipients shall be safe for chronic preclinical toxicology studies in dog. Challenges: Conventional suspension in dog resulted in low oral ...Read More
The reaction of b-chloroacrolein with 1 equiv of 2-aminophenol in DMF proceeds smoothly to afford 11-hydroxy derivative of chromenoquinoline in good yield. This single pot method allows for a rapid access to a variety of chromenoquinolines or oxepinoquinolines depending on the nature of b-chloroacrolein used. The structures were established by spectroscopic data ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.